Key Drivers
- Healthy margins
- Low leverage
- Working-capital strain
AIAI Summary
Aptar is a cash‑generative, low‑leverage industrial whose near‑term equity outcome is now binary and event‑driven — DrugSorb‑ATR De Novo timing and CEO succession will likely determine whether the stock re‑rates on pharma upside or reverts to a mid‑single‑digit growth valuation, so treat ATR as an opportunistic, timing‑dependent play rather than a conviction buy.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Healthy margins
- •Low leverage
- •Working-capital strain
ATR generates strong earnings and cash flow with healthy margins and low leverage, but sizable working capital, large intangibles and recent Q4 softness pose operational and quality risks.
Price Behavior
Key Price Behavior Insights:
- •Falling volatility
- •Broken consolidation
- •Support test
Clear short-term downtrend: ATR and price fell over the last month, the stock broke the 135–140 consolidation and now tests prior support near $121–124 while resistance clusters at $142–145.
Accelerated drop from $129.50 to $121.06 over three days, signaling rising downside volatility
Sentiment & News
Key News Insights:
- •Institutional accumulation
- •CEO succession
- •Analyst downgrade
Multiple institutions accumulated large Aptar positions amid active investor outreach and a surprising insider sale/CEO appointment, while analysts repeatedly ranked ATR a strong sell, signaling mixed institutional confidence and analyst caution.
The combination of concentrated buying and management change may support stock interest, but repeated sell ratings from analysts could cap near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings